Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Linker Length Matters, Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency

(2014) Michela Silacci et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

(2014) S. Brack et al.   MOLECULAR CANCER THERAPEUTICS

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

(2014) Helga Radner et al.   ARTHRITIS RESEARCH & THERAPY

Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

(2014) Jens A. A. Fischer et al.   Arthritis & Rheumatology

Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases

(2014) Thomas Thomaidis et al.   Oncology Research and Treatment

Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones

(2013) David W. Banner et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis

(2013) Giulia Benedetti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain

(2012) Daniel Schlatter et al.   mAbs

Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis

(2011) Marije I. Koenders et al.   ARTHRITIS AND RHEUMATISM

Anti-TNF Treatment in Rheumatoid Arthritis

(2011) Janina Geiler et al.   CURRENT PHARMACEUTICAL DESIGN

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-  Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

(2010) R. Deng et al.   DRUG METABOLISM AND DISPOSITION

To switch or to change class—the biologic dilemma in rheumatoid arthritis

(2010) Edith Villeneuve et al.   Nature Reviews Rheumatology

Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF  single-chain Fv antibody (ESBA105) designed for local therapeutic use

(2009) D M Urech et al.   ANNALS OF THE RHEUMATIC DISEASES

Structure of IL-17A in Complex with a Potent, Fully Human Neutralizing Antibody

(2009) Stefan Gerhardt et al.   JOURNAL OF MOLECULAR BIOLOGY

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

(2009) Andrea Rubbert-Roth et al.   ARTHRITIS RESEARCH & THERAPY